Teva Pharma (TEVA): Street is Too High, Cutting PT - RBC

RBC Capital analyst, Randall Stanicky, reiterated his Outperform rating on shares of Teva Pharma (NYSE: TEVA) but cut his price target to $42 from $51 after the company's business outlook update. The analyst sees a Copaxone 3TW generic delay as increasingly necessary to support both the P&L and upside.

TEVA is now "past" its guidance event but the analyst thinks Street numbers are still too high across most of the sector offering first time guidance in February.

For an analyst ratings summary and ratings history on Teva Pharma click here. For more ratings news on Teva Pharma click here.

Shares of Teva Pharma closed at $35.10 yesterday.

You May Also Be Interested In

• Kotak Downgrades 360 ONE WAM Ltd (360ONE:IN) to Add (2)
• Warpaint London plc (W7L:LN) PT Raised to GBP5.80 at Berenberg
• Moncler SpA (MONC:IM) (MONRY) PT Raised to EUR65 at JPMorgan